TABLE 1.

Selected Demographic and Clinical Information for Patients Included in Analysis

Parameter	Data
Age (y)	71.5 (66.8–72.0)
Caucasian race	100%
PSA (ng/mL)
PET1	24.0 (12.1–47.1)
PET2	11.0 (6.1–27.0)
Interval between PET1 and PET2 (d)	84 (70–91.5)
Therapy initiated
Abiraterone	88%
Enzalutamide	13%

Qualitative data are percentages based on 16-patient sample size; continuous data are median and IQR. Mention of race is relevant in the context of prostate cancer because Black patients tend to have more aggressive underlying biology of disease and less access to health care in the United States.